Projects funded by the NCN

Information on the principal investigator and host institution

Information of the project and the call

Keywords

Equipment

Delete all

STING protein activation combined with anti-vascular agent as a novel strategy for anticancer therapy

2018/31/B/NZ5/01825

Keywords:

tumor microenvironment,cancer immunotherapy antivascular therapy

Descriptors:

  • NZ5_7: Human disease treatment
  • NZ4_12: Other related subjects
  • NZ6_1: Adaptive and innate immunity

Panel:

NZ5 - Human and animal noninfectious diseases: etiology, mechanisms, diagnosis and treatment of diseases, poisonings and injuries (without neurological diseases)

Host institution :

Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie - Państwowy Instytut Badawczy, Oddział w Gliwicach

woj. śląskie

Other projects carried out by the institution 

Principal investigator (from the host institution):

dr hab. Ryszard Smolarczyk 

Number of co-investigators in the project: 6

Call: OPUS 16 - announced on 2018-09-14

Amount awarded: 784 160 PLN

Project start date (Y-m-d): 2019-06-28

Project end date (Y-m-d): 2023-06-27

Project duration:: 48 months (the same as in the proposal)

Project status: Project completed

Project description

Download the project description in a pdf file

Note - project descriptions were prepared by the authors of the applications themselves and placed in the system in an unchanged form.

Information in the final report

  • Publication in academic press/journals (4)
  • Articles in post-conference publications (8)
  1. Antitumor effect of anti-vascular therapy with STING agonist depends on the tumor microenvironment context
    Authors:
    Justyna Czapla, Alina Drzyzga, Sybilla Matuszczak, Tomasz Cichoń, Marek Rusin, Magdalena Jarosz-Biej, Ewelina Pilny, Ryszard Smolarczyk
    Academic press:
    Frontiers in Oncology (rok: 2023, tom: 13, strony: 1249524), Wydawca: Frontiers
    Status:
    Published
    DOI:
    10.3389/fonc.2023.1249524 - link to the publication
  2. Vascular disrupting agents in cancer therapy
    Authors:
    Smolarczyk R, Czapla J, Jarosz-Biej M, Czerwinski K, Cichoń T
    Academic press:
    Eur J Pharmacol (rok: 2021, tom: 891, strony: 173692), Wydawca: Elsevier
    Status:
    Published
    DOI:
    10.1016/j.ejphar.2020.173692 - link to the publication
  3. The Proper Administration Sequence of Radiotherapy and Anti-Vascular Agent—DMXAA Is Essential to Inhibit the Growth of Melanoma Tumors
    Authors:
    Alina Drzyzga, Tomasz Cichoń, Justyna Czapla, Magdalena Jarosz-Biej, Ewelina Pilny, Sybilla Matuszczak, Piotr Wojcieszek, Zbigniew Urbaś, Ryszard Smolarczyk
    Academic press:
    Cancers (rok: 2021, tom: 13, strony: 3924), Wydawca: MDPI
    Status:
    Published
    DOI:
    10.3390/cancers13163924 - link to the publication
  4. Prognostic Significance of STING Immunoexpression in Relation to HPV16 Infection in Patients with Squamous Cell Carcinomas of Oral Cavity and Oropharynx
    Authors:
    Beata Biesaga, Ryszard Smolarczyk, Anna Mucha-Małecka, Justyna Czapla, Janusz Ryś, Krzysztof Małecki
    Academic press:
    Biomedicines (rok: 2022, tom: 10(10), strony: 2538), Wydawca: MDPI
    Status:
    Published
    DOI:
    10.3390/biomedicines10102538 - link to the publication
  1. The tumor microenvironment polarization as a goal of cancer immunotherapy
    Authors:
    Ryszard Smolarczyk
    Conference:
    XXVI Gliwice Scientific Meetings (rok: 2022, ), Wydawca: Gliwice Scientific Meetings
    Data:
    konferencja 18-19.11.2022
    Status:
    Published
  2. Anticancer effect of vascular disrupting agent (CA4P) in combination with STING agonist (cGAMP) in murine breast cancer and melanoma therapy
    Authors:
    Smolarczyk R, Drzyzga A, Czapla J, Matuszczak S, Pilny E, Rusin M, Cichoń T
    Conference:
    XXV Gliwice Scientific Meetings (rok: 2021, ), Wydawca: Gliwice Scientific Meetings
    Data:
    konferencja 18-20.11.2021
    Status:
    Published
  3. Diverse tumor microenvironment composition influences the effectiveness of therapy with the use of a STING agonist and an anti-vascular compound
    Authors:
    Justyna Czapla, Alina Drzyzga, Sybilla Matuszczak, Tomasz Cichoń, Marek Rusin, Ewelina Pilny, Magdalena Jarosz-Biej, Ryszard Smolarczyk
    Conference:
    47th FEBS Congress (rok: 2023, ), Wydawca: FEBS Open Bio (Wiley Online Library)
    Data:
    konferencja 08-12.07.2023
    Status:
    Published
  4. Irinotecan changes cellular levels of STING protein and enhances responsiveness of breast cancer tumors to STING protein agonist
    Authors:
    Ryszard Smolarczyk, Justyna Czapla, Alina Drzyzga, Marek Rusin, Joanna Ciepły, Edyta Komisarczyk, Tomasz Cichoń
    Conference:
    47th FEBS Congress (rok: 2023, ), Wydawca: FEBS Open Bio (Wiley Online Library)
    Data:
    konferencja 08-12.07.2023
    Status:
    Published
  5. The effectiveness of vascular disrupting agent (CA4P) combined with STING agonist (2'3'-cGAMP) in anticancer therapy
    Authors:
    A.Drzyzga, T. Cichoń, J. Czapla, E. Pilny, S. Matuszczak, R. Smolarczyk
    Conference:
    The 5th Warsaw Conference on Perspectives of Molecular Oncology: Molecular Immunology of Cancer (rok: 2020, ), Wydawca: Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie - Państwowy Instytut Badawczy
    Data:
    konferencja 23-24 wrzesień 2020
    Status:
    Published
  6. Combination of the STING protein agonist (cGAMP) and the anti-vascular agent - combretastatin – as an effective murine breast cancer therapy
    Authors:
    Smolarczyk R, Drzyzga A, Czapla J, Matuszczak S, Pilny E, Cichoń T
    Conference:
    The 6th Warsaw Conference on Perpectives of Molecular Oncology (rok: 2021, ), Wydawca: Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie - Państwowy Instytut Badawczy
    Data:
    konferencja 15-16.09.2021
    Status:
    Published
  7. STING agonist cGAMP and vascular disrupting agent induce anti-tumor response of poorly immunogenic tumor by inflaming tumor microenvironment
    Authors:
    Czapla J, Drzyzga A, Matuszczak S, Pilny E, Ciepła J, Cichoń T, Jarosz-Biej M, Halemba M, Rupik W, Smolarczyk R
    Conference:
    XXVI Gliwice Scientific Meetings (rok: 2022, ), Wydawca: Gliwice Scientific Meetings
    Data:
    konferencja 18-19.11.2022
    Status:
    Published
  8. The antitumor effectiveness of anti-vascular agent (CA4P) and STING protein agonist (cGAMP) combination in the treatment of breast tumor and melanoma
    Authors:
    Smolarczyk R, Drzyzga A, Czapla J, Matuszczak S, Pilny E, Cichoń T, Rusin M
    Conference:
    8th Central European Congress of Life Sciences EUROBIOTECH (rok: 2022, ), Wydawca: Eurobiotech
    Data:
    konferencja 20-22.06.2022
    Status:
    Published

O Narodowym Centrum Nauki

Finansowanie nauki

Współpraca zagraniczna

Centrum prasowe

Deklaracja dostępności
Przetwarzanie danych osobowych
Polityka cookies

Partnerzy